A study published in the Journal of Clinical Investigation found that men with defective mismatch repair (dMMR) prostate cancer had worse overall survival (OS).
The researchers assessed 127 biopsy specimens from 124 patients with advanced prostate cancer who underwent treatment at the Royal Marsden Hospital in London. Using polymerase chain reaction assay, they determined dMMR status based on either loss of mismatch repair protein expression or microsatellite instability (MSI).
We've shown that prostate cancer with DNA repair defects (encompassing dMMR) have a very poor prognosis overall – similar is seen in breast and ovarian cancer with HR defects – do very poorly without DNA damaging treatment (but very well with) https://t.co/5GlDFJ9obK
— Dr Eileen Parkes (@eileen_parkes) September 6, 2018
Among the cohort, 8.1% had dMMR cancers. The dMMR and a high degree of MSI defects are found most commonly in colorectal, endometrial, and gastrointestinal cancers and occur less commonly in other cancers, including prostate cancer.
From the time of diagnosis, the median OS was 8.5 years among those with non-dMMR prostate cancers compared with 4.1 years for those with dMMR prostate cancer (P=0.07). From the time of hormone therapy initiation, the median OS was 7.0 years for the non-dMMR group versus 3.8 years for the dMMR group (P=0.003).
Smoking status affects prostate cancer survival.
Cost savings were observed with docetaxel versus abiraterone acetate for prostate cancer.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.